ArticleCureus2024
A Hemangiopericytoma in the External Auditory Canal: A Rare Clinical Presentation and Management.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hemangiopericytomas (HPCs) are rare vascular tumors originating from pericytes, with a predilection for the musculoskeletal system and occasional occurrence in the head and neck region. HPCs arising in the external auditory canal (EAC) are exceptionally rare, making their diagnosis and management a clinical challenge. A 71-year-old male presented with a six-month history of a painless, progressively enlarging mass in his right EAC, accompanied by tinnitus and hearing loss. Physical examination revealed a mobile, reddish mass in the concha of the left auricle, nearly occluding the EAC. Contrast-enhanced computed tomography of the temporal bone demonstrated a heterogeneously enhancing mass with erosion of adjacent structures. Histopathological examination and immunohistochemistry confirmed the diagnosis of an HPC. The tumor was surgically excised, and the patient underwent adjuvant radiotherapy. Over a two-year follow-up period, no recurrence was observed. This case highlights the rarity of HPCs in the EAC and underscores the importance of considering this diagnosis in patients presenting with atypical EAC masses. A multidisciplinary approach, including surgical excision and radiotherapy, is crucial for achieving favorable outcomes and reducing the risk of recurrence. Long-term follow-up is essential due to the potential for late recurrence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.